FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Medicines Agency decided that Victoza's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Victoza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: HbA1c gives an indication of how well the blood glucose is controlled.
Estonian: HbA1c näitab, kui hästi on vere glükoosisisaldus reguleeritud.
English: Other information about Victoza
Estonian: Muu teave Victoza kohta
English: It is given independent of meals and preferably at the same time each day.
Estonian: Ravimit soovitatakse manustada sõltumata söögikordadest iga päev samal ajal.
English: In addition to the above studies, Victoza was shown to be effective in reducing adverse cardiovascular (heart and blood vessels) effects.
Estonian: Lisaks eeltoodud uuringutele tõendati Victoza efektiivsust kardiovaskulaarsete (südame ja veresoonte) kõrvalnähtude vähendamisel.
English: Cardiovascular events occurred in 13% (608 out of 4668) of patients taking Victoza compared with 14.9% (694 out of 4672) of patients taking placebo.
Estonian: Patsiente, kellel esines kardiovaskulaarseid juhte, oli Victoza uuringurühmas 13% (608 patsienti 4668st) ning platseeborühmas 14,9% (694 patsienti 4672st).
English: Victoza was compared with placebo and all patients also received standard care.
Estonian: Victozat võrreldi platseeboga ja kõik patsiendid said standardravi.
English: What is Victoza and what is it used for?
Estonian: Mis on Victoza ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Victoza have been included in the summary of product characteristics and the package leaflet.
Estonian: Victoza ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: • on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;
Estonian: • ainsa ravimina, kui metformiini (samuti II tüüpi diabeedi ravim) kasutamine ei ole soovitatav;
English: Victoza was effective at controlling blood glucose in six main studies involving 4,155 adults with type 2 diabetes.
Estonian: Victoza oli vere glükoosisisalduse reguleerimisel efektiivne kuues põhiuuringus, milles osales 4155 II tüüpi diabeediga täiskasvanud patsienti.
English: It is not intended to provide practical advice on how to use Victoza.
Estonian: Hindamisaruandes ei anta Victoza kasutamise praktilisi nõuandeid.
English: This is a summary of the European public assessment report (EPAR) for Victoza.
Estonian: See on ravimi Victoza Euroopa avaliku hindamisaruande kokkuvõte.
English: Victoza is a solution for injection available in pre-filled pens (6 mg/ml).
Estonian: Victoza on süstelahus, mida turustatakse eeltäidetud pensüstaldes (6 mg/ml).
English: Why is Victoza approved?
Estonian: Miks Victoza heaks kiideti?
English: The study involved 9,340 patients with type 2 diabetes who already had cardiovascular disease (such as angina, heart attack or stroke).
Estonian: Uuringus osales 9340 II tüüpi diabeediga patsienti, kellel juba oli kardiovaskulaarne haigus (stenokardia, südameinfarkt või insult).
English: The starting dose of Victoza is 0.6 mg. After at least one week, the dose is increased to 1.2 mg.
Estonian: Victoza algannus on 0,6 mg. Vähemalt ühe nädala pärast suurendatakse annust 1,2 mg-ni.
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose (sugar) in the blood or when the body is unable to use insulin effectively.
Estonian: II tüüpi diabeet on haigus, mille korral kõhunäärmes ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: Victoza is used:
Estonian: Victozat kasutatakse järgmiselt:
English: The most common side effects with Victoza (seen in more than 1 patient in 10) are nausea and diarrhoea.
Estonian: Victoza kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on iiveldus ja kõhulahtisus.
English: In some patients, the dose can be further increased to 1.8 mg one week later to achieve better control of blood glucose.
Estonian: Osadel patsientidel võib ühe nädala pärast vere glükoosisisalduse paremaks reguleerimiseks olla vaja suurendada annust 1,8 mg-ni.
English: Victoza contains the active substance liraglutide.
Estonian: Victoza sisaldab toimeainena liraglutiidi.
English: In these studies, the main measure of effectiveness was the reduction in the amount of a substance in the blood called glycosylated haemoglobin (HbA1c) after six months or one year of treatment.
Estonian: Nendes uuringutes oli efektiivsuse põhinäitaja glükoseerunud hemoglobiini (HbA1c) sisalduse vähenemine veres pärast kuus kuud või üks aasta kestnud ravi.
English: • as an ‘add-on' to other diabetes medicines.
Estonian: • koos teiste diabeediravimitega.
English: Victoza is a medicine used in addition to diet and exercise in adults who have type 2 diabetes.
Estonian: Victoza on ravim, mida kasutatakse koos dieedi ja füüsilise koormusega II tüüpi diabeediga täiskasvanutel.
English: What are the risks associated with Victoza?
Estonian: Mis riskid Victozaga kaasnevad?
English: Results from this study show that Victoza at a dose of 1.2 mg reduced HbA1c by 0.8 percentage points, whereas Victoza at a dose of 1.8 mg led to reductions of 1.1 percentage points.
Estonian: Selle uuringu tulemuste kohaselt vähendab Victoza 1,2 mg annus HbA1c sisaldust 0,8% võrra ja Victoza 1,8 mg annus vähendab 1,1% võrra.
English: This helps with the control of blood glucose levels.
Estonian: See aitab vere glükoosisisaldust reguleerida.
English: For the full list of all side effects and restrictions with Victoza, see the package leaflet.
Estonian: Victoza kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: When Victoza is added to existing treatment containing metformin or a thiazolidinedione, the doses of these medicines do not have to be changed.
Estonian: Victoza lisamisel olemasolevale ravile metformiini või tiasolidiindioonravimiga ei muutu nende ravimite annused.
English: For practical information about using Victoza, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Victoza kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How does Victoza work?
Estonian: Kuidas Victoza toimib?
English: When Victoza is added to treatment with a sulphonylurea or insulin, the doctor should consider lowering the dose of the other medicine to reduce the risk of having hypoglycaemia (low blood glucose).
Estonian: Victoza lisamisel ravile sulfonüüluurearavimi või insuliiniga peab arst vajaduse korral vähendama teise ravimi annust, et ennetada hüpoglükeemia riski (vere normaalsest väiksem glükoosisisaldus).
English: For more information about treatment with Victoza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Victozaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Combinations containing Victoza were more effective at controlling blood glucose than combinations without the medicine.
Estonian: Victozat sisaldavad ravimikombinatsioonid olid vere glükoosisisalduse reguleerimisel efektiivsemad kui need, mis seda ravimit ei sisaldanud.
English: Victoza is given by the patient once a day by injection under the skin in the abdomen, thigh or upper arm.
Estonian: Patsient manustab Victozat ise üks kord ööpäevas nahaaluse süstina kõhupiirkonda, reide või õlavarde.
English: Adding Victoza to treatment with basal insulin plus metformin reduced HbA1c by 0.7 percentage points, compared with 0.4 points when adding Victoza to insulin aspart.
Estonian: Victoza lisamine basaalinsuliini ja metformiini kombinatsioonile vähendas HbA1c sisaldust 0,7% võrra ja Victoza lisamine aspartinsuliini annusele 0,4% võrra.
English: This compared with a reduction of 0.5 percentage points with glimepiride.
Estonian: Glimepiriidi kasutades oli sama näitaja 0,5%.
English: How is Victoza used?
Estonian: Kuidas Victozat kasutatakse?
English: Dual therapies containing Victoza and metformin or glimepiride led to reductions in HbA1c of around 1 percentage point compared with no reduction without Victoza.
Estonian: Victozat ja metformiini või glimepiriidi sisaldav kaksikravi vähendas HbA1c sisaldust ligikaudu 1% võrra.
English: What benefits of Victoza have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Victoza kasulikkus?
English: Victoza used on its own was more effective at controlling blood glucose than glimepiride.
Estonian: Victoza ainsa ravimina oli vere glükoosisisalduse reguleerimisel glimepiriidist efektiivsem.
English: The triple therapies containing Victoza led to a reduction of between 1.3 and 1.5 percentage points compared with a reduction equal or less than 0.5 points without Victoza.
Estonian: Kolmikravi koos Victozaga vähendas HbA1c sisaldust 1,3-1,5% võrra ja kuni 0,5%, kui Victozat ei kasutatud.
English: In another triple therapy study, Victoza was compared with a single dose of a short-acting insulin, insulin aspart, when added to treatment with basal insulin (a long-acting insulin) plus metformin.
Estonian: Teises kolmikravi uuringus võrreldi Victozat lühiajalise toimeajaga insuliini (aspartinsuliini) üksikannusega selle lisamisel basaalinsuliini ja metformiini kombinatsioonile.
English: In two ‘triple therapy' studies, Victoza with metformin and either glimepiride or rosiglitazone (a thiazolidinedione) were compared with treatments that included placebo or another anti-diabetes medicine instead of Victoza.
Estonian: Kahes kolmikravi uuringus võrreldi Victozat koos metformiini ja glimepiriidi või rosiglitasooniga (teatud tiasolidiindioonravim) platseebot või muud diabeediravimit kui Victoza sisaldava raviga.
English: The medicine can only be obtained with a prescription.
Estonian: Victoza on retseptiravim.
English: This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food.
Estonian: Victoza toimeaine liraglutiid on inkretinomimeetikum ehk aine, mis toimib sarnaselt sooles tekkivate hormoonide inkretiinidega, suurendades toidu mõjul kõhunäärme eritatava insuliini kogust.
English: In one ‘monotherapy' study, Victoza on its own was compared with glimepiride (a sulphonylurea).
Estonian: Ühes monoteraapia uuringus võrreldi ainsa ravimina kasutatavat Victozat glimepiriidiga (teatud sulfonüüluurearavim).
English: In two ‘dual therapy' studies, Victoza plus metformin or Victoza plus glimepiride were compared with metformin or glimepiride taken with a placebo (a dummy treatment).
Estonian: Kahes duoteraapia (ravi kahe ravimiga) uuringus võrreldi Victoza ja metformiini või glimepiriidi kasutamist platseebo (näiv ravim) ja metformiini või glimepiriidi kasutamisega.
English: Keppra levetiracetam
Estonian: Keppra levetiratsetaam
English: The use of the infusion should be temporary.
Estonian: Infusioonina manustamine peab olema ajutine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Keppra on 29 September 2000.
Estonian: Euroopa Komisjon andis Keppra müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 29. septembril 2000.
English: The full EPAR for Keppra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Keppra kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: All of the patients were taking at least one other anti-epileptic medicine.
Estonian: Kõik patsiendid võtsid veel vähemalt üht epilepsiaravimit.
English: In all of these studies, the main measure of effectiveness was the change in the number of seizures before and during treatment.
Estonian: Kõigis nendes uuringutes oli efektiivsuse põhinäitaja episoodide arvu muutus enne ja pärast ravi.
English: It is available as tablets (250 mg, 500 mg, 750 mg and 1,000 mg), as an oral solution (100 mg/ml), and as a concentrate that is made up into a solution for infusion (drip into a vein, 100 mg/ml).
Estonian: Seda turustatakse tablettidena (250 mg, 500 mg, 750 mg ja 1000 mg), suukaudse lahusena (100 mg/ml) ja kontsentraadina, millest valmistatakse infusioonilahus (veeni tilgutatav lahus, 100 mg/ml).
English: The CHMP decided that Keppra's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Keppra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: However, there were too few patients aged below 12 years to support the use of Keppra for this type of seizure in this age group.
Estonian: Samas ei olnud katsetes alla 12aastasi patsiente piisavalt, et toetada Keppra kasutamist selles vanuserühmas.
English: In both groups, 73% of the patients experienced no seizures for six months once on an adequate dose.
Estonian: Mõlemas uuringurühmas ei olnud 73% patsientidest episoode 6 kuu jooksul alates ajast, kui nad hakkasid saama piisavat ravimiannust.
English: This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear.
Estonian: See on epilepsia vorm, kus aju ühe poolkera elektriline liigtalitlus tekitab selliseid sümptomeid nagu ühe kehapoole järsud tõmblused, kuulmis-, haistmis- või nägemishäired, tuimus või äkiline hirmutunne.
English: Other information about Keppra:
Estonian: Muu teave Keppra kohta
English: This document is a summary of the European public assessment report (EPAR) for Keppra.
Estonian: See on ravimi Keppra Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Keppra.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Epilepsy is caused by excessive electrical activity in the brain.
Estonian: Epilepsiat põhjustab aju elektriline liigtalitlus.
English: Why has Keppra been approved?
Estonian: Miks Keppra heaks kiideti?
English: What is Keppra?
Estonian: Mis on Keppra?
English: The oral solution may be mixed in a glass of water before it is taken.
Estonian: Suukaudse lahuse tohib segada enne manustamist klaasi veega.
English: For more information about treatment with Keppra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Keppraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Keppra tablets are swallowed with liquid.
Estonian: Keppra tabletid neelatakse koos vedelikuga.
English: Lower doses are used in patients who have problems with their kidneys (such as older patients).
Estonian: Väiksemaid annuseid kasutatakse neeruprobleemidega patsientidel (näiteks eakatel).
English: • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Estonian: • primaarsed generaliseerunud toonilis-kloonilised episoodid (rasked epilepsiaepisoodid, millega kaasneb teadvusekaotus) vähemalt 12-aastastel patsientidel, kellel on idiopaatiline generaliseerunud epilepsia (epilepsia liik, mille tekkepõhjust peetakse geneetiliseks).
English: The exact way in which levetiracetam works is still unclear but it seems to interfere with a protein called synaptic vesicle protein 2A, which is found in the spaces between nerves and is involved in the release of chemical messengers from nerve cells.
Estonian: Levetiratsetaami täpne toimemehhanism ei ole veel teada, kuid see näib sekkuvat sünapsipõiekeste proteiini 2A toimesse.
English: With Keppra at a dose of 2,000 mg, the reduction was 27%, and with 3,000 mg, it was around 39%.
Estonian: Keppra kasutamisel annuses 2000 mg vähenes episoodide sagedus 27% ja annuse 3000 mg korral ligikaudu 39%.
English: For the full list of all side effects reported with Keppra, see the package leaflet.
Estonian: Keppra kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Keppra is a medicine that contains the active substance levetiracetam.
Estonian: Keppra on ravim, mis sisaldab toimeainena levetiratsetaami.
English: This helps Keppra to stabilise electrical activity in the brain and prevent seizures.
Estonian: Sel viisil aitab ravim stabiliseerida aju elektrilist talitlust ning ennetada epilepsiaepisoode.
English: The most common side effects with Keppra (seen in more than 1 patient in 10) are nasopharyngitis (inflammation of the nose and throat), somnolence (sleepiness), and headache.
Estonian: Keppra kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on nina-neelupõletik, unisus ja peavalu.
English: The patient's treatment was continued for 20 weeks once they were taking their full dose.
Estonian: Pärast täisannuse saavutamist jätkati patsientide ravi 20 nädalat.
English: Keppra must not be used in people who are hypersensitive (allergic) to levetiracetam, to other pyrrolidone derivatives (medicines with a similar structure to levetiracetam), or to any of the other ingredients.
Estonian: Kepprat ei tohi kasutada patsiendid, kes on levetiratsetaami või muude pürrolidooniderivaatide (ravimid, mille struktuur sarnaneb levetiratsetaami omaga) või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: • for partial onset seizures, placebo treatment reduced the weekly number of seizures by 6 to 7%, while the reduction with Keppra at a dose of 1,000 mg per day was between 18 and 33%, depending on the study.
Estonian: • Partsiaalsete episoodide korral vähendas platseebo episoodide arvu nädalas 6-7% võrra, Keppra annus 1000 mg ööpäevas olenevalt uuringust 18-33% võrra.
English: Keppra was also more effective than placebo in children;
Estonian: Keppra oli platseebost efektiivsem ka lastel.
English: Keppra has also been compared with placebo in 314 patients aged between one month and 17 years;
Estonian: Kepprat võrreldi ka platseeboga 314 patsiendil vanuses 1 kuust 17 aastani.
English: The oral solution is recommended when starting treatment in children under six years old or weighing less than 25 kg.
Estonian: Suukaudset lahust soovitatakse kasutada alla 6-aastaste või alla 25 kg kehamassiga laste ravi alustamisel.
English: The study measured how many patients remained free of seizures for six months once they had reached their effective dose.
Estonian: Uuringus registreeriti nende patsientide arv, kellel efektiivse annuse saamise algusest alates ei olnud 6 kuu jooksul esinenud episoode.
English: This can be increased up to 21 mg/kg twice a day.
Estonian: Annust tohib suurendada annuseni 21 mg/kg kaks korda ööpäevas.
English: In babies aged between one and six months, the starting dose is 7 mg/kg twice a day, using the oral solution.
Estonian: Imikutel vanuses 1-6 kuud on algannus 7 mg/kg kaks korda ööpäevas, kasutatakse suukaudset lahust.
English: What is the risk associated with Keppra?
Estonian: Mis riskid Keppraga kaasnevad?
English: How does Keppra work?
Estonian: Kuidas Keppra toimib?
English: What benefit has Keppra shown during the studies?
Estonian: Milles seisneb uuringute põhjal Keppra kasulikkus?
English: • for tonic-clonic seizures, the number of seizures fell by an average of 28% in the patients receiving placebo, compared with 57% in those receiving Keppra.
Estonian: • Toonilis-klooniliste episoodide korral vähenes episoodide sagedus platseebot saanud patsientidel keskmiselt 28% võrra ja Kepprat saanud patsientidel 57% võrra.
English: In patients aged between six months and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day.
Estonian: 6-kuulistel kuni 17-aastastel patsientidel kehamassiga alla 50 kg on algannus 10 mg kehamassi kg kohta kaks korda ööpäevas, seda annust tohib suurendada kaks korda ööpäevas manustatava annuseni 30 mg/kg.
English: Keppra can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Estonian: Kepprat tohib kasutada ainsa ravimina vähemalt 16-aastastel patsientidel, kellel on äsja diagnoositud epilepsia, et ravida sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalseid episoode.
English: • in primary generalised tonic-clonic seizures, Keppra was compared with placebo in 164 patients aged four years or over.
Estonian: • Primaarsed generaliseerunud toonilis-kloonilised epilepsiaepisoodid; Kepprat võrreldi platseeboga 164 vähemalt 4-aastasel patsiendil.
English: Keppra used on its own has been studied in 579 patients with partial-onset seizures aged 16 years and over, who received either Keppra or carbamazepine (another anti-epileptic medicine) for up to two years.
Estonian: Keppra kasutamist ainsa ravimina uuriti 579 vähemalt 16-aastasel partsiaalsete episoodidega patsiendil, kes said kuni kahe aasta jooksul Kepprat või karbamasepiini (samuti epilepsiaravim).
English: Keppra can also be used as an add-on to other anti-epileptic medicines to treat:
Estonian: Kepprat tohib kasutada ka teiste epilepsiaravimite lisaravimina, et ravida järgmisi seisundeid:
English: • in myoclonic seizures, Keppra was studied in 122 patients aged 12 years and over, who received either Keppra or placebo in addition to their normal anti-epileptic medicine for up to 30 weeks;
Estonian: • Müokloonilised epilepsiaepisoodid; Keppra efektiivsust uuriti 122 vähemalt 12-aastasel patsiendil, kes said kuni 30 nädalat lisaks tavalisele epilepsiaravimile Kepprat või platseebot.
English: When Keppra is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day.
Estonian: Keppra lisamisel muule epilepsiaravimile vähemalt 12-aastastel patsientidel kehakaaluga üle 50 kg on algannus 500 mg kaks korda ööpäevas.
English: When Keppra is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Estonian: Keppra kasutamisel ainsa ravimina on algannus 250 mg kaks korda ööpäevas, seda suurendatakse kahe nädala pärast annuseni 500 mg kaks korda ööpäevas.
English: • for myoclonic seizures, the number of seizure days per week was halved in 58% of the patients receiving Keppra and in 23% of the patients receiving placebo;
Estonian: • Müoklooniliste episoodide korral oli patsiente, kellel vähenes epilepsiaepisoodidega päevade arv nädalas vähemalt poole võrra, Keppra rühmas 58% ja platseeborühmas 23%.
English: • myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12
Estonian: • müokloonilised episoodid (lühiajalised šokitaolised lihaste või lihasrühmade tõmblused) vähemalt 12-aastastel patsientidel, kellel on noorukiea müoklooniline epilepsia;
English: Keppra was as effective as carbamazepine in keeping patients free of seizures when taken on its own for partial onset seizures.
Estonian: Keppra kasutamine partsiaalsete episoodide ainsa ravimina oli episoodide ennetamisel sama efektiivne kui karbamasepiin.
English: • partial-onset seizures with or without generalisation in patients from one month of age;
Estonian: • sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalsed episoodid vähemalt 1-kuulistel patsientidel;